NCT03811457

Immunotherapy With CD19 CAR T-cells in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma

Completed NA Last updated 22 January 2019

What this trial tests

NA trial testing Welgenaleucel in Lymphoma Leukemia in 9 participants. Completed in 31 December 2018.

Timeline

1 June 2017

Primary endpoint
31 December 2018

31 December 2018

Quick facts

Lead sponsor	UWELL Biopharma
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	1 June 2017
Primary completion	31 December 2018
Estimated completion	31 December 2018
Sites	1 location across China

Drugs / interventions tested

• Welgenaleucel

Conditions studied

• Lymphoma Leukemia — all drugs for Lymphoma Leukemia →

Sponsor

UWELL Biopharma — full company profile →

Who can join

Under 70, any sex, with Lymphoma Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

B cell malignancies comprise a heterogeneous group of neoplasms including a vast majority of non-Hodgkin's lymphomas (NHL), lymphoblastic leukemias (ALL) and chronic lymphocytic leukemias (CLL). Current treatments for B cell malignancies include chemotherapy, radiation therapy, bone marrow transplantation, and peripheral blood stem cell transplantation. Despite these treatment modalities, most patients will remain incurable. Welgenaleucel (UWC19) is a CD19-directed genetically-modified autologous immunotherapy. This study is designed to evaluate safety and feasibility of administering Welgenaleucel (UWC19) transduced with anti-CD19 lentiviral vector to patients with advanced refractory hematologic malignancies, including DLBCL and ALL.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Cancer Stem Cell for Tumor Therapy.
   Huang B, Yan X, Li Y. · · 2021 · cited 27× · PMID 34638298 · DOI 10.3390/cancers13194814